FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

716046009: Mepolizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2016. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3304563013 Mepolizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3304564019 Mepolizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
366681000195119 mepolizumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
823821000172112 mépolizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Mepolizumab (substance) Is a Substance with interleukin 5 receptor antagonist mechanism of action (substance) true Inferred relationship Some
Mepolizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin receptor antagonist (disposition) false Inferred relationship Some
Mepolizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin 5 receptor antagonist true Inferred relationship Some
Mepolizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing mepolizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Mepolizumab (substance) Inferred relationship Some 1
Product containing only mepolizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Mepolizumab (substance) Inferred relationship Some 1
Product containing only mepolizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Mepolizumab (substance) Inferred relationship Some 1
Mepolizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Mepolizumab (substance) Inferred relationship Some 1
Mepolizumab 100 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Mepolizumab (substance) Inferred relationship Some 1
Mepolizumab 100 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Mepolizumab (substance) Inferred relationship Some 1
Mepolizumab therapy Direct substance True Mepolizumab (substance) Inferred relationship Some 1

Reference Sets

Description inactivation indicator reference set

Back to Start